CoChat

The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden

Open access
Boross, P., Jansen, J. H. M., de Haij, S., Beurskens, F. J., van der Poel, C. E., Bevaart, L., Nederend, M., Golay, J., van de Winkel, J. G. J., Parren, P. W. H. I., Leusen, J. H. W. · 2011 · Haematologica
Cited by 74

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

BACKGROUND: CD20 monoclonal antibodies are widely used in clinical practice. Antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and direct cell death have been suggested to be important effector functions for CD20 antibodies. However, their specific contributions to the in vivo mechanism of action of CD20 immunotherapy have not been well defined. DESIGN AND METHODS: Here we studied the in vivo mechanism of action of type I (rituximab and ofatumumab) and type II (HuMab-11B8) CD20 antibodies in a peritoneal, syngeneic, mouse model with EL4-CD20 cells using low and high tumor burden. RESULTS: Interestingly, we observed striking differences in the in vivo mechanism of action of CD20 antibodies dependent on tumor load. In conditions of low tumor burden, complement was sufficient for tumor killing both for type I and type II CD20 antibodies. In contrast, in conditions of high tumor burden, activating FcγR (specifically FcγRIII), active complement and complement receptor 3 were all essential for tumor killing. Our data suggest that complement-enhanced antibody-dependent cellular cytotoxicity may critically affect tumor killing by CD20 antibodies in vivo. The type II CD20 antibody 11B8, which is a poor inducer of complement activation, was ineffective against high tumor burden. CONCLUSIONS: Tumor burden affects the in vivo mechanism of action of CD20 antibodies. Low tumor load can be eliminated by complement alone, whereas elimination of high tumor load requires multiple effector mechanisms.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.2011.047159

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 74

Metadata

Authors
Boross, P., Jansen, J. H. M., de Haij, S., Beurskens, F. J., van der Poel, C. E., Bevaart, L., Nederend, M., Golay, J., van de Winkel, J. G. J., Parren, P. W. H. I., & Leusen, J. H. W.
Venue
Haematologica
Published
2011-08-31
Volume
96
Issue
12
Pages
1822-1830
ISSN
  • 0390-6078 (ISSN-L)
  • 1592-8721
OpenAlex
W2137752130
Cited by
74
References
3
FWCI
7.58
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. https://app.cochat.ai/papers/10.3324/haematol.2011.047159
The paper
Boross, P., Jansen, J. H. M., de Haij, S., Beurskens, F. J., van der Poel, C. E., Bevaart, L., Nederend, M., Golay, J., van de Winkel, J. G. J., Parren, P. W. H. I., & Leusen, J. H. W. (2011). The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden. Haematologica. https://doi.org/10.3324/haematol.2011.047159

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.